CV Home - Archive ouverte HAL

	Relationship between cetuximab target-mediated pharmacokinetics and progression-free survival in metastatic colorectal cancer patients Sarah Lobet , Gilles Paintaud , Nicolas Azzopardi , Christophe Passot , Morgane Caulet Clinical Pharmacokinetics, 2023, 62 (9), pp.1263-1274. ⟨10.1007/s40262-023-01270-2⟩ Journal articles hal-04285346v1
	Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX) David Tougeron , Sheik Emambux , Laure Favot , Thierry Lecomte , Ewa Wierzbicka-Hainaut OncoImmunology, 2020, 9 (1), pp.1848058. ⟨10.1080/2162402X.2020.1848058⟩ Journal articles hal-03149030v1
	In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration Thomas Secher , Emilie Dalonneau , Marion Ferreira , Christelle Parent , Nicolas Azzopardi Journal of Controlled Release, 2019, 303, pp.24-33. ⟨10.1016/j.jconrel.2019.04.005⟩ Journal articles hal-02179896v1
	CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis Amina Bensalem , Denis Mulleman , Gilles Thibault , Nicolas Azzopardi , Philippe Goupille British Journal of Clinical Pharmacology, 2019, ⟨10.1111/bcp.14102⟩ Journal articles hal-02376303v1
	Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited Amina Bensalem , Denis Mulleman , Gilles Paintaud , Nicolas Azzopardi , Valerie Gouilleux-Gruart Clinical Pharmacokinetics, 2019, ⟨10.1007/s40262-019-00826-5⟩ Journal articles hal-02316414v1
	Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans David Ternant , Nicolas Azzopardi , William Raoul , Theodora Bejan-Angoulvant , Gilles Paintaud Clinical Pharmacokinetics, inPress, ⟨10.1007/s40262-018-0680-3⟩ Journal articles hal-01821717v1
	Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice Christophe Arnoult , Guillaume Brachet , Diana Cadena Castaneda , Nicolas Azzopardi , Christophe Passot Journal of Immunology, 2017, 199 (2), pp.418-424. ⟨10.4049/jimmunol.1601246⟩ Journal articles hal-02019721v1
	Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group Mira Tout , Anne-Laure Gagez , Stéphane Lepretre , Valérie Gouilleux-Gruart , Nicolas Azzopardi Clinical Pharmacokinetics, 2017, 56 (6), pp.635 - 647. ⟨10.1007/s40262-016-0470-8⟩ Journal articles hal-01769807v1
	Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients Morgane Caulet , Thierry Lecomte , Olivier Bouché , Jérôme Rollin , Valérie Gouilleux-Gruart Clinical Pharmacokinetics, 2016, 55 (11), pp.1381 - 1394. ⟨10.1007/s40262-016-0406-3⟩ Journal articles hal-01769811v1
	Cetuximab pharmacokinetics influences overall survival in head and neck cancer patients Yoann Pointreau , Nicolas Azzopardi , David Ternant , Gilles Calais , Gilles Paintaud Therapeutic Drug Monitoring, 2016, 38 (5), pp.567-72. ⟨10.1097/FTD.0000000000000321⟩ Journal articles hal-01769813v1
	Pharmacokinetics of adalimumab in Crohn’s disease David Ternant , Konstantinos Karmiris , Séverine Vermeire , Celine Desvignes , Nicolas Azzopardi European Journal of Clinical Pharmacology, 2015, 71 (9), pp.1155-1157. ⟨10.1007/s00228-015-1892-1⟩ Journal articles hal-01769822v1
	Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia Nicolas Azzopardi , Sophie Dupuis-Girod , David Ternant , Anne-Emmanuelle Fargeton , Isabelle Ginon mAbs, 2015, 7 (3), pp.630 - 637. ⟨10.1080/19420862.2015.1022693⟩ Journal articles hal-01769884v1
	Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab Jérôme Rollin , Audrey Payancé , Valérie Gouilleux-Gruart , Michelle Boisdron-Celle , Nicolas Azzopardi Pharmacogenomics, 2015, 16 (18), pp.2035-2043. ⟨10.2217/pgs.15.139⟩ Journal articles hal-02381189v1
	VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations Virginie Herve , Nathalie Rabbe , Laurent Guilleminault , Flora Paul , Laurène Schlick mAbs, 2014, 6 (6), pp.1638 - 1648. ⟨10.4161/mabs.34454⟩ Journal articles hal-01769888v1
	Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies Christophe Passot , Nicolas Azzopardi , Sylvaine Renault , Nadine Baroukh , Christophe Arnoult mAbs, 2014, 5 (4), pp.614 - 619. ⟨10.4161/mabs.24815⟩ Journal articles hal-01769897v1
	Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system Laurent Guilleminault , Nicolas Azzopardi , Christophe Arnoult , Julien Sobilo , Virginie Hervé Journal of Controlled Release, 2014, 196, pp.344-354. ⟨10.1016/j.jconrel.2014.10.003⟩ Journal articles hal-02376374v1
	Influence of plasma exchange on rituximab pharmacokinetics Nicolas Azzopardi , Maud François , Emeline Laurent , Gilles Paintaud , Béatrice Birmelé British Journal of Clinical Pharmacology, 2013, 76 (3), pp.486 - 488. ⟨10.1111/bcp.12167⟩ Journal articles hal-01769901v1
	The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors Agnes Maillet , Laurent Guilleminault , Etienne Lemarié , Stephanie Lerondel , Nicolas Azzopardi Pharmaceutical Research, 2011, 28 (9), pp.2147 - 2156. ⟨10.1007/s11095-011-0442-5⟩ Journal articles hal-01769936v1
	Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients Nicolas Azzopardi , Therry Lecomte , David Ternant , Michele Boisdron-Celle , Friedrich Piller Fundamental & Clinical Pharmacology, 2011, 25, pp.34-34 Journal articles hal-00616314v1
	Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients Nicolas Azzopardi , Thierry Lecomte , David Ternant , Michelle Boisdron-Celle , Friedrich Piller Clinical Cancer Research, 2011, 17 (19), pp.6329 - 6337. ⟨10.1158/1078-0432.CCR-11-1081⟩ Journal articles hal-01769933v1
	Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis D Chu Miow Lin , D. Mulleman , N. Azzopardi , G Griffoul-Espitalier , P Valat Scandinavian Journal of Rheumatology, 2010, 39 (1), pp.97 - 98. ⟨10.3109/03009740903177745⟩ Journal articles hal-01769938v1
	Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis D. Chu Miow Lin , D. Mulleman , N. Azzopardi , I. Griffoul-Espitalier , J.-P. Valat Scandinavian Journal of Rheumatology, 2010, 39 (1), pp.97-98 Journal articles hal-00616813v1
	Aerosoltherapy for lung tumors using the monoclonal antibody cetuximab Agnes Maillet , Laurent Guilleminault , Nicolas Azzopardi , Jerome Montharu , Laurent Vecellio Journal of Thoracic Oncology, 2009, 4 (9), pp.S600-S600 Journal articles hal-00616858v1
	An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab Nicolas Ceze , David Ternant , Friedrich Piller , Danielle Degenne , Nicolas Azzopardi Therapeutic Drug Monitoring, 2009, 31 (5), pp.597-601 Journal articles hal-00521871v1
	Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis Juliette Thariat , Nicolas Azzopardi , Frederic Peyrade , Vincent Launay-Vacher , Jose Santini Journal of Clinical Oncology, 2008, 26 (25), pp.4223-4225 Journal articles hal-00616934v1

	Relationship between rituximab concentration and autoantibody levels in anti-neutrophil cytoplasmic antibody associated vasculitis A Bensalem , D Ternant , N. Azzopardi , G. Paintaud , V Gouilleux-Gruart EULAR 2019, Jun 2019, MADRID, Spain Conference poster hal-02149477v1

	Effect of the social environment on olfaction and social skills in WT and mouse model of autism Caroline Gora , Ana Dudas , Lucas Court , Anil Annamneedi , Gaëlle Lefort 2023 Preprints, Working Papers, ... hal-04312827v1

Nicolas Azzopardi

Presentation

Publications

Relationship between cetuximab target-mediated pharmacokinetics and progression-free survival in metastatic colorectal cancer patients

Skin inflammatory response and efficacy of anti-epidermal growth factor receptor therapy in metastatic colorectal cancer (CUTACETUX)

In a murine model of acute lung infection, airway administration of a therapeutic antibody confers greater protection than parenteral administration

CD4+ count‐dependent concentration‐effect relationship of rituximab in rheumatoid arthritis

Non-Linear Rituximab Pharmacokinetics and Complex Relationship between Rituximab Concentrations and Anti-Neutrophil Cytoplasmic Antibodies (ANCA) in ANCA-Associated Vasculitis: The RAVE Trial Revisited

Influence of Antigen Mass on the Pharmacokinetics of Therapeutic Antibodies in Humans

Crucial Role for Immune Complexes but Not FcRn in Immunization against Anti–TNF-α Antibodies after a Single Injection in Mice

Influence of FCGR3A-158V/F Genotype and Baseline CD20 Antigen Count on Target-Mediated Elimination of Rituximab in Patients with Chronic Lymphocytic Leukemia: A Study of FILO Group

Bevacizumab Pharmacokinetics Influence Overall and Progression-Free Survival in Metastatic Colorectal Cancer Patients

Cetuximab pharmacokinetics influences overall survival in head and neck cancer patients

Pharmacokinetics of adalimumab in Crohn’s disease

Dose – response relationship of bevacizumab in hereditary hemorrhagic telangiectasia

Significant effect of VEGFA polymorphisms on the clinical outcome of metastatic colorectal cancer patients treated with FOLFIRI-cetuximab

VEGF neutralizing aerosol therapy in primary pulmonary adenocarcinoma with K-ras activating-mutations

Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies

Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system

Influence of plasma exchange on rituximab pharmacokinetics

The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors

Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients

Cetuximab Pharmacokinetics Influences Progression-Free Survival of Metastatic Colorectal Cancer Patients

Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis

Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis

Aerosoltherapy for lung tumors using the monoclonal antibody cetuximab

An Enzyme-Linked Immunosorbent Assay for Therapeutic Drug Monitoring of Cetuximab

Cetuximab pharmacokinetics in end-stage kidney disease under hemodialysis

Relationship between rituximab concentration and autoantibody levels in anti-neutrophil cytoplasmic antibody associated vasculitis

Effect of the social environment on olfaction and social skills in WT and mouse model of autism